CN111848615B - 吡啶酮衍生物及包含其的抗流感病毒药物组合物 - Google Patents

吡啶酮衍生物及包含其的抗流感病毒药物组合物 Download PDF

Info

Publication number
CN111848615B
CN111848615B CN202010817434.6A CN202010817434A CN111848615B CN 111848615 B CN111848615 B CN 111848615B CN 202010817434 A CN202010817434 A CN 202010817434A CN 111848615 B CN111848615 B CN 111848615B
Authority
CN
China
Prior art keywords
group
compound
radical
pyridone derivative
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010817434.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111848615A (zh
Inventor
陈力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Kerui Pharmaceutical Co ltd
Original Assignee
Jiangxi Caishi Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810044308.4A external-priority patent/CN110041327B/zh
Priority claimed from CN201811517425.4A external-priority patent/CN111303147B/zh
Application filed by Jiangxi Caishi Pharmaceutical Technology Co ltd filed Critical Jiangxi Caishi Pharmaceutical Technology Co ltd
Publication of CN111848615A publication Critical patent/CN111848615A/zh
Application granted granted Critical
Publication of CN111848615B publication Critical patent/CN111848615B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN202010817434.6A 2018-01-17 2019-01-16 吡啶酮衍生物及包含其的抗流感病毒药物组合物 Active CN111848615B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2018100443084 2018-01-17
CN201810044308.4A CN110041327B (zh) 2018-01-17 2018-01-17 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN2018115174254 2018-12-12
CN201811517425.4A CN111303147B (zh) 2018-12-12 2018-12-12 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN201980000078.4A CN110637016B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
PCT/CN2019/071902 WO2019141179A1 (zh) 2018-01-17 2019-01-16 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980000078.4A Division CN110637016B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用

Publications (2)

Publication Number Publication Date
CN111848615A CN111848615A (zh) 2020-10-30
CN111848615B true CN111848615B (zh) 2022-05-17

Family

ID=67301986

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202010817434.6A Active CN111848615B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物及包含其的抗流感病毒药物组合物
CN201980000078.4A Active CN110637016B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN202010817435.0A Active CN111848616B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物及其用于制备抗流感病毒药物的用途
CN202010817035.XA Active CN111848614B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物及抗流感病毒药物组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201980000078.4A Active CN110637016B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN202010817435.0A Active CN111848616B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物及其用于制备抗流感病毒药物的用途
CN202010817035.XA Active CN111848614B (zh) 2018-01-17 2019-01-16 吡啶酮衍生物及抗流感病毒药物组合物

Country Status (13)

Country Link
US (1) US11247993B2 (cg-RX-API-DMAC7.html)
EP (1) EP3753936B1 (cg-RX-API-DMAC7.html)
JP (1) JP7352297B2 (cg-RX-API-DMAC7.html)
KR (1) KR102477187B1 (cg-RX-API-DMAC7.html)
CN (4) CN111848615B (cg-RX-API-DMAC7.html)
AU (1) AU2019210414B2 (cg-RX-API-DMAC7.html)
CA (1) CA3088926A1 (cg-RX-API-DMAC7.html)
ES (1) ES3074017T3 (cg-RX-API-DMAC7.html)
PH (1) PH12020551264A1 (cg-RX-API-DMAC7.html)
PT (1) PT3753936T (cg-RX-API-DMAC7.html)
SG (1) SG11202011447UA (cg-RX-API-DMAC7.html)
WO (1) WO2019141179A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202007143B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US11286262B2 (en) 2017-10-06 2022-03-29 Shionogi & Co., Ltd. Stereoselective process for preparing substituted polycyclic pyridone derivatives
HUE069183T2 (hu) * 2018-02-28 2025-02-28 Novartis Ag 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére
WO2020205835A1 (en) * 2019-04-01 2020-10-08 Nikang Therapeutics, Inc. Fused polycyclic pyridone compounds as influenza virus replication inhibitors
CN111909174B (zh) 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
CN112574170A (zh) * 2019-09-29 2021-03-30 江西东邦药业有限公司 一种二苯并七元环衍生物及其制备方法和应用
CN115135646B (zh) * 2019-12-23 2024-05-17 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
CN113045589B (zh) * 2019-12-27 2024-08-23 广东东阳光药业股份有限公司 流感病毒复制抑制剂及其用途
CN112898346B (zh) * 2020-01-23 2023-11-10 南京知和医药科技有限公司 水溶性多环化合物及其药物组合物和用途
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种(3s,4r)3-氨基-4(甲氧基甲基)吡咯烷-1-甲酸叔丁酯及其合成方法
CN120289488A (zh) * 2020-08-11 2025-07-11 石家庄迪斯凯威医药科技有限公司 多环化合物及其药物组合物和用途
CN115385932A (zh) * 2021-05-22 2022-11-25 江西彩石医药科技有限公司 吡啶酮衍生物的中间体及其制备方法
CN117003766B (zh) * 2022-10-08 2024-02-02 石家庄迪斯凯威医药科技有限公司 一种抗流感病毒衍生物及其用途
WO2024098856A1 (zh) * 2022-11-09 2024-05-16 石家庄迪斯凯威医药科技有限公司 一种抗流感病毒衍生物及其用途
CN116789556A (zh) * 2023-05-26 2023-09-22 康化(上海)新药研发有限公司 一种含环丙氧基乙胺的制备方法
WO2026145578A1 (zh) * 2024-12-30 2026-07-09 江西科睿药业有限公司 固体分散体、药物组合物及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803260A (zh) * 2009-06-15 2012-11-28 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物
JP5971830B1 (ja) * 2015-04-28 2016-08-17 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグ
WO2017104691A1 (ja) * 2015-12-15 2017-06-22 塩野義製薬株式会社 キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬
JP6249434B1 (ja) * 2016-08-10 2017-12-20 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2620436T (lt) 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
CN105764904B (zh) * 2013-09-12 2020-02-11 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
JP6806413B2 (ja) 2016-02-03 2021-01-06 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803260A (zh) * 2009-06-15 2012-11-28 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物
JP5971830B1 (ja) * 2015-04-28 2016-08-17 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグ
WO2017104691A1 (ja) * 2015-12-15 2017-06-22 塩野義製薬株式会社 キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬
JP6249434B1 (ja) * 2016-08-10 2017-12-20 塩野義製薬株式会社 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物

Also Published As

Publication number Publication date
KR102477187B1 (ko) 2022-12-12
AU2019210414A1 (en) 2020-09-03
SG11202011447UA (en) 2020-12-30
CA3088926A1 (en) 2019-07-25
ES3074017T3 (en) 2026-07-16
PT3753936T (pt) 2026-07-10
CN111848616A (zh) 2020-10-30
WO2019141179A1 (zh) 2019-07-25
CN110637016A (zh) 2019-12-31
CN111848615A (zh) 2020-10-30
CN110637016B (zh) 2020-08-18
US20190367517A1 (en) 2019-12-05
EP3753936A1 (en) 2020-12-23
US11247993B2 (en) 2022-02-15
EP3753936B1 (en) 2026-04-08
ZA202007143B (en) 2022-04-28
KR20200118062A (ko) 2020-10-14
CN111848616B (zh) 2021-11-23
JP7352297B2 (ja) 2023-09-28
EP3753936A4 (en) 2022-03-23
CN111848614A (zh) 2020-10-30
CN111848614B (zh) 2021-11-23
JP2021511374A (ja) 2021-05-06
PH12020551264A1 (en) 2021-05-31
AU2019210414B2 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
CN111848614B (zh) 吡啶酮衍生物及抗流感病毒药物组合物
CN110041327B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
JP7079794B2 (ja) アミノピリジン化合物ならびにその調製および使用のための方法
KR102084109B1 (ko) 캡 의존적 엔도뉴클레아제 저해제 및 항인플루엔자 약을 조합하는 것을 특징으로 하는 인플루엔자 치료용 의약
CN111303147B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
CA3165238A1 (en) Kras mutant protein inhibitors
JP2010536825A (ja) 肝炎などのウイルス感染の治療用イミダゾ[1,2−a]ピラジン化合物
CA2928541A1 (en) Inhibitors of human immunodeficiency virus replication
AU2015335783B2 (en) Tricyclic atropisomer compounds
JP2023513373A (ja) P2x3修飾薬
KR20250005125A (ko) NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체
CN116783195A (zh) N-苯基氨基羰基吡啶基-、嘧啶基和苯并-托烷作为gpr65的调节剂
AU2016382372A1 (en) Sulfonamide derivative and preparation method and use thereof
JP2018522814A (ja) ピリジン化合物
KR20250038236A (ko) 코로나바이러스 감염 치료용 화합물
AU2021275146A1 (en) Piperidine-2,6-diones as small molecule degraders of Helios and methods of use
JP2024546600A (ja) 疾患の治療のための二環式化合物の使用
AU2023204968B2 (en) Novel isoindolinone derivative compounds as caspase inhibitors
HK40032909A (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
CN115677703A (zh) 吡啶酮类化合物及其用途
EA045400B1 (ru) Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства
HK40070400B (en) Oxadiazole transient receptor potential channel inhibitors
EA051595B1 (ru) Соединения пиридазина для ингибирования nlrp3
WO2026002036A1 (zh) 一种化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20260423

Address after: No. 188, Qingfeng Avenue, Zhanggong District, Ganzhou City, Jiangxi Province, 341000

Patentee after: Jiangxi Kerui Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: Room 201, building 2, 196 Qingfeng Avenue, Zhanggong District, Ganzhou City, Jiangxi Province

Patentee before: Jiangxi Caishi Pharmaceutical Technology Co.,Ltd.

Country or region before: China